Revenue Growth: Zomedica's revenue of $6.26 million for Q1 2025 represents a 14.23% increase year-over-year, showcasing the strong demand for its veterinary diagnostics products. However, the QoQ decrease of 14.65% raises questions about seasonal fluctuations and ongoing operational efficiencies.
Profitability Metrics: The gross profit margin saw an improvement to 65.75%, up from 62.48% in Q4 2024. However, the net income for the quarter was a loss of $9.16 million, reflecting a -43.46% change year-over-year, underscoring persistent cost management issues that must be addressed.
Cash Position: As of the end of Q1 2025, Zomedica had $10.94 million in cash and cash equivalents, down from $12.95 million at the beginning of the quarter. The total assets stood at $243.7 million, supported by a solid current ratio of 11.50.